SeekingAlpha · Feb 3, 2026
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026
Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock here.
AL
NASDAQ · ALT
Altimmune, Inc.
Healthcare · Biotechnology
$2.02
Down-$0.02 (-0.98%)
Updated Nov 3, 2026, 9:27 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 380.39M
- P/E ratio
- -4.59
- Dividend yield
- 0.00%
- 52-week range
- $1.99 – $4.04
- Volume
- 2.74M
- Avg. volume
- 4.9M
Price performance · ALT
ALT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
ALT closed at $2.02 after 21 trading sessions, down 24.34% for the selected period.
- Last close
- $2.02
- Period change
- -24.34%
- Period low
- $2.02
- Period high
- $2.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $2.07 | $2.1063 | $2.01 | $2.02 | 2.74M |
| Oct 30, 2026 | $2.135 | $2.135 | $1.99 | $2.04 | 3.52M |
| Oct 29, 2026 | $2.105 | $2.18 | $2.10 | $2.14 | 2.68M |
| Oct 28, 2026 | $2.03 | $2.10 | $1.995 | $2.10 | 4.33M |
| Oct 27, 2026 | $2.07 | $2.15 | $2.01 | $2.04 | 4.97M |
| Oct 26, 2026 | $2.13 | $2.15 | $2.02 | $2.05 | 3.5M |
| Oct 23, 2026 | $2.16 | $2.20 | $2.06 | $2.12 | 2.6M |
| Oct 22, 2026 | $2.20 | $2.245 | $2.15 | $2.17 | 3.09M |
| Oct 21, 2026 | $2.31 | $2.35 | $2.19 | $2.23 | 4.5M |
| Oct 20, 2026 | $2.22 | $2.32 | $2.20 | $2.30 | 2.31M |
| Oct 19, 2026 | $2.22 | $2.26 | $2.18 | $2.23 | 2.61M |
| Oct 16, 2026 | $2.365 | $2.3691 | $2.17 | $2.20 | 4.24M |
| Oct 15, 2026 | $2.31 | $2.38 | $2.29 | $2.36 | 3.35M |
| Oct 14, 2026 | $2.40 | $2.41 | $2.29 | $2.31 | 5.63M |
| Oct 13, 2026 | $2.56 | $2.56 | $2.43 | $2.43 | 3.72M |
| Oct 12, 2026 | $2.59 | $2.625 | $2.56 | $2.56 | 2.16M |
| Oct 9, 2026 | $2.60 | $2.64 | $2.57 | $2.61 | 2.68M |
| Oct 8, 2026 | $2.66 | $2.66 | $2.55 | $2.60 | 4.93M |
| Oct 7, 2026 | $2.64 | $2.74 | $2.63 | $2.66 | 3.17M |
| Oct 6, 2026 | $2.70 | $2.70 | $2.64 | $2.67 | 7.63M |
| Oct 5, 2026 | $2.73 | $2.7467 | $2.65 | $2.67 | 3.84M |
Latest ALT news
The latest Smart Investors Daily articles mentioning ALT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ALT research
Overview
Company profile and research snapshot.
Company profile
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Evercore ISI Group | Outperform | — |
| Jun 22, 2026 | Leerink Partners | Outperform | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | Citizens | Market Outperform | — |
| Mar 16, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 28, 2026
Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet
Yahoo · Jan 6, 2026
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.
Yahoo · Jan 5, 2026
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDAGAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agoni
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
